Kate Therapeutics Debuts With $51 Million Series A To Develop Next-Generation Genetic Medicines To Treat Muscle and Heart Diseases
Kate Therapeutics Inc., a next-generation gene therapy company, has emerged from stealth mode after securing a $51 million Series A financing round. The funding was co-led by Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. Additionally, the company has granted Astellas Pharma Inc. an exclusive worldwide license to develop, manufacture, and commercialize KT430 for the treatment of X-linked myotubular myopathy (XLMTM).
IPOs Could Be Headed for a Rocky Road in 2023
Initial public offerings appear likely to remain sluggish for at least several months to start 2023, while special purpose acquisition companies, which provide businesses with alternative paths to public listings, face headwinds of their own. Hear what University of Florida professor Jay Ritter, has to say about a possible IPO drought.
The Threat of a Down Round: How Startups Can Adapt To Protect Their Value
The current funding environment might have a lot of founders questioning how to stay sustainable. How do you address this tough situation? Miguel Fernandez, co-founder and CEO at Capchase gives insights on how startups can better deal with the current funding environment.
I am BIO Podcast: Featuring UF Ventures Director Jackson Streeter
Recently, our very own Jackson Streeter was featured on the I Am BIO (Biotechnology Innovation Organization) Podcast. Hear how UF is spending over 1 billion dollars in research and how their work with AAV could help cure all types of genetic disorders.
